Parkinson disease
57,539views
00:00 / 00:00
Flashcards
Parkinson disease
of complete
Questions
USMLE® Step 1 style questions USMLE
of complete
Memory Anchors and Partner Content
External References
First Aid
2024
2023
2022
2021
Akinesia in Parkinson disease p. 725
Antimuscarinic drugs
Parkinson disease p. 563
Antipsychotic drugs p. 591
Parkinson-like syndrome p. 250
Dopamine p. 241, 332
Parkinson disease p. 563
Gait disturbance
Parkinson disease p. 537
Gait disturbances
Parkinson disease p. 725
MAO inhibitors p. 593
Parkinson disease p. 563
Metoclopramide p. 407
Parkinson-like syndrome p. 250
Muscarinic antagonists p. 240, 706
Parkinson disease p. 563
Nausea
Parkinson disease drugs p. 564
Neurons p. 502
Parkinson disease p. 563
Parkinson disease p. 534
basal ganglia lesions p. 524
benztropine for p. 240
dopaminergic pathways p. 509
drug therapy for p. 563
Lewy bodies p. 534
neurotransmitters for p. 507
nigrostriatal pathway and p. 509
presentation p. 725
proteasome and p. 46
resting tremor in p. 533
seborrheic dermatitis association p. 484
trihexyphenidyl p. 240
Parkinson-like syndrome p. 250
Reserpine
Parkinson-like syndrome p. 250
Rigidity in Parkinson disease p. 725
Substantia nigra
Parkinson disease p. 725
Transcript
Content Reviewers
Contributors
Parkinson’s disease, which is sometimes called Parkinson disease, Parkinson’s, or PD, is a movement disorder where the dopamine-producing neurons in the substantia nigra of the brain undergo degeneration.
Parkinson’s is one of the most common neurological disorders. It’s a progressive, adult-onset disease, and it gets more common with age. Most of the time, there’s no known cause. But in a few cases, there might be a genetic cause, like mutations in the PINK1, parkin, or alpha synuclein genes, and in rare cases, Parkinsonian symptoms may be caused by MPTP, a toxic impurity that can be found in the recreational drug MPPP or desmethylprodine, which is a synthetic opioid.
In other people, one or more risk factors, rather than a single outright cause, might contribute to Parkinson’s, for example pesticide exposure or DNA variants in genes like LRRK2.
No matter what the cause is, Parkinson’s derives from the death of dopamine-producing, or dopaminergic, neurons in the substantia nigra. The name substantia nigra means “black substance,” since it is darker than other brain regions when you look at a slice of the brain on an autopsy.
We usually refer to the substantia nigra as if it’s in a single location, but there are actually two of these regions in the brain, one on each side of the midbrain. The substantia nigra is a part of the basal ganglia, a collection of brain regions that control movement through their connections with the motor cortex.
In Parkinson’s, these darkened areas of substantia nigra gradually disappear. Under a microscope, Lewy bodies, which are eosinophilic, round inclusions made of alpha-synuclein protein are present in the affected substantia nigra neurons before they die. The function of alpha-synuclein is unknown, as well as the significance of Lewy bodies, and they are both found in other diseases like Lewy body dementia and multiple system atrophy.
The substantia nigra actually can be split into two sub-regions.
First, there’s the pars reticulata, which receives signals from another part of the basal ganglia called the striatum, which is a term for the caudate and putamen put together, and relays messages to the thalamus via neurons rich in the neurotransmitter GABA, also known as gamma-aminobutyric acid.
Summary
Parkinson's is a progressive movement disorder caused by degeneration of dopamine-producing neurons in the substantia nigra, specifically in the pars compacta, which leads to resting tremor, rigidity, problems initiating movement, and postural instability, and for which therapy primarily focuses on increasing brain dopamine.
There is no cure for this condition, but medications can increase dopamine levels in the brain and control tremors. There is also deep-brain stimulation, which involves an implantable device that directly sends electrical signals to the basal ganglia that counteract the abnormal signaling in Parkinson's.
Sources
- "Robbins Basic Pathology" Elsevier (2017)
- "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
- "Pathophysiology of Disease: An Introduction to Clinical Medicine 7/E (ENHANCED EBOOK)" McGraw Hill Professional (2014)
- "CURRENT Medical Diagnosis and Treatment 2020" McGraw Hill Professional (2019)
- "Parkinson's disease" The Lancet (2015)
- "Parkinson's disease" The Lancet (2004)